RJ QuickJul 27, 20211 minDrive Therapeutics awarded a Phase 1 SBIR from the NSFDrive was recently awarded a $256,000 Phase 1 SBIR grant from the NSF to help continue development of our novel, aptamer based inhibitors...
RJ QuickFeb 5, 20211 minDrive Receives Funding from NC Biotech CenterDrive Therapeutics of Research Triangle Park received $100,000 to develop a novel nucleic acid therapy to block angiogenesis,...
RJ QuickJul 9, 20202 minWelcome Doug Gooding to the Drive Therapeutics Team!Doug has agreed to join the team as CEO and help us navigate fundraising, early stage company formation, and relationship formation...
RJ QuickApr 20, 20201 minCatch Up With Us on GustAs a fledgling biotech startup, we are looking for ways to raise funding and meet potential investors while #stayingathome. We have...